Analytical and clinical evaluation of a new tumor marker in breast cancer: CA 27.29

1992 ◽  
Vol 7 (1) ◽  
pp. 43-46 ◽  
Author(s):  
M. Correale ◽  
I. Abbate ◽  
G. Gargano ◽  
A. Catino ◽  
C.D. Dragone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Breast Disease ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Ca 15.3 ◽  
Lower Specificity ◽  
Apparently Healthy

Evaluation of a radioimmunoassay for a new tumor marker, named CA 27.29, recently proposed for use in breast cancer patients, is reported in this study. After considering the analytical performance, the clinical study was directed to a control group of 66 apparently healthy subjects (Controls), a group of 25 women with benign breast disease (BBD) and a group of 164 breast cancer patients divided into primary before any treatment (M-), in follow-up with no evidence of disease (NED) and presence of metastases (M+). When compared to CA 15.3, our results showed similar sensitivity of both markers with a slightly lower specificity for CA 27.29. In some cases, however, CA 27.29 elevation appears earlier than CA 15.3 as a sign of metastases. We thus propose their associated use.

Longitudinal follow-up of breast cancer patients with the tumor markers CA 549 and CA 15.3

1995 ◽  
Vol 10 (1) ◽  
pp. 30-34 ◽  
Author(s):  
L. Vankrieken ◽  
F. Heureux ◽  
J. Longueville ◽  
R. De Hertogh
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Clinical Situation ◽  
Breast Cancer Patients ◽  
Significant Information ◽  
Ca 15.3 ◽  
Cutoff Levels

In order to verify the efficiency of the tumor markers CA 15.3 and CA 549 in the follow-up of breast cancer patients, it was necessary first to check the cutoff levels of each tumor marker in women with an increased age-related risk, but with no evidence of disease. From 132 serum samples in this age group, we confirmed the CA 549 cutoff level of 12.1 U/ml. However, the cutoff of CA 15.3 was 34 U/ml, which is higher than previously reported in the literature. Fifty-two breast cancer patients with or without metastases at the time of entry into the study were followed for 2 to 3 years with both tumor markers. The sensitivity, specificity and the test efficiency for the presence of metastases were analyzed with each tumor marker. Taking into account the different cutoff levels, we concluded that both tumor markers can be used independently to follow the clinical situation of patients. In several cases an increase in both tumor markers was observed before a clinical diagnosis of metastases could be made. Combination of these two tumor markers gave no more significant information about the patient's clinical situation than each tumor marker alone.

Ca 15.3 as a Tumour Marker in Breast Cancer

1987 ◽  
Vol 2 (3) ◽  
pp. 135-142 ◽  
Author(s):  
Peter Schmidt-Rhode ◽  
Klaus-Dieter Schulz ◽  
Gerhard Sturm ◽  
Anette Raab-Frick ◽  
Helge Prinz
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Tumour Marker ◽  
Primary Treatment ◽  
Breast Diseases ◽  
Breast Cancer Patients ◽  
Ca 15.3 ◽  
Healthy Females

CA 15.3 is an antigenic determinant associated with human mammary carcinomas. Two murine monoclonal antibodies have been raised against the determinants, and an immunoradiometric assay (IRMA-Kit, Centocor, USA) has been developed to determine the antigen levels in plasma of cancer patients. Based on the 99% confidence limit of healthy women, plasma values above 30 U/ml are considered abnormal. Plasma samples from 357 women were examined in the present study. Healthy females (n = 84) ranged below the cut-off level between < 10 and 29 U/ml. Higher values were found in 12.5% of benign breast diseases and in 23.6% of breast cancer patients, including all stages. Depending on the stage of the disease, there were elevated levels in 11% of operable breast cancer patients preoperatively, in 7% of the cases with no evidence of disease after primary treatment and in 63.5% ofpatients with disseminated mammary carcinoma. In metastasized breast cancer the frequency and the degree of abnormal titers were closely related to the extent of the metastatic disease. Follow-up examinations of 63 patients under cytotoxic therapy showed CA 15.3 changes correlating well with the clinical course in up to 90% of the antigen positive cases. The present data indicate that CA 15.3 may be useful in the surveillance of breast cancer patients. However in our study one third of the patients with metastatic breast cancer did not show any increase in CA 15.3 and must be regarded as antigen negative.

Study of serum tumor markers CEA, CA 15.3 and CA 27.29 as diagnostic parameters in patients with breast carcinoma

1995 ◽  
Vol 10 (1) ◽  
pp. 24-29 ◽  
Author(s):  
L. Rodríguez De Paterna ◽  
F. Arnaiz ◽  
J. Estenoz ◽  
B. Ortuño ◽  
E. Lanzós
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Serum Levels ◽  
Breast Diseases ◽  
Breast Cancer Patients ◽  
Ca 15.3 ◽  
Combined Use ◽  
Malignant Breast

Serum levels of CEA, CA 15.3 and CA 27.29 were measured during the follow-up of 499 breast cancer patients. Studies included three different groups of women: 82 blood donors free of disease, 42 patients with non-malignant breast diseases and 499 breast cancer patients. After the determinaion of cut-off values, serum levels of tumor markers did not show significant elevations in benign breast diseases. On the basis of our results CA 15.3 (sensitivity = 57%; accuracy = 87%) was the most effective marker, CA 27.29 (sensitivity = 62%; accuracy = 83%) was the most sensitive and CEA (sensitivity = 45%; accuracy = 81%) was the least sensitive and effective marker. The combined use of markers was evaluated by step-wise logistic regression analysis. The regression coefficients showed that CA 15.3 (coeff. = 2.97) and CA 27.29 (coeff. = 1.46) were suitable for the detection of possible metastases during follow-up. Finally, we studied the relationship between pT, pN, pM and circulating levels of CA 15.3 and CA 27.29.

scholarly journals Influence of Orally Administered Probiotic Lactobacillus Strains on Vaginal Microbiota in Women with Breast Cancer during Chemotherapy: A Randomized Placebo-Controlled Double-Blinded Pilot Study

Breast Care ◽  
2017 ◽  
Vol 12 (5) ◽  
pp. 335-339 ◽  
Author(s):  
Julian Marschalek ◽  
Alex Farr ◽  
Marie-Louise Marschalek ◽  
Konrad J. Domig ◽  
Wolfgang Kneifel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Intervention Group ◽  
Postmenopausal Breast Cancer ◽  
Vaginal Microbiota ◽  
Lactobacillus Species ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Nugent Score

Background: Due to chemotherapy and estrogen deprivation therapy, genitourinary syndrome of menopause is a common condition in breast cancer patients. We aimed to determine the effect of an orally administered Lactobacillus preparation on the vaginal microbiota in breast cancer patients. Methods: Postmenopausal breast cancer patients receiving chemotherapy, with vaginal atrophy and an intermediate vaginal microbiota (Nugent score 4-6), were either randomized to the intervention group receiving probiotic capsules of 4 Lactobacillus species or to the control group receiving placebo twice daily for 2 weeks. Consecutive vaginal swabs were taken at baseline, 1 day after administration of the last capsule (follow-up 1), and after 1 week (follow-up 2) in 22 patients (11 vs. 11). Results: We observed a positive influence on the vaginal microbiota in 7/11 (63%) women in the intervention group, and 4/11 (36%) women in the control group. There was a shift in Nugent score towards normal microbiota levels in the intervention group (-1.3 at follow-up 1, -0.45 at follow-up 2) and a significant deterioration of the Nugent score in the control group (+0.4 at follow-up 1, +2.5 at follow-up 2). Conclusion: The orally administered Lactobacillus preparation has the potential to improve the vaginal microbiota in women undergoing chemotherapy for breast cancer.

Activity limitation and clustering of symptoms in breast cancer patients

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 8540-8540
Author(s):  
R. Sawhney ◽  
M. E. Sehl ◽  
H. Sanati ◽  
W. A. Satariano ◽  
A. Naeim
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Correlation Coefficients ◽  
Activity Limitation ◽  
Cancer Surveillance ◽  
Survey Study ◽  
Control Group ◽  
Significant Activity ◽  
Breast Cancer Patients

8540 Background: While previous cancer symptom research has been focused on individual symptoms, more recent studies have attempted to identify symptom clusters in breast cancer patients. However, there has been no large study that has examined both clustering of symptoms and activity limitation in breast cancer patients. Methods: Data were taken from a survey study of 1,011 patients found to have histologically confirmed breast cancer, identified by the Metropolitan Detroit Cancer Surveillance System. Patients were surveyed at both 3 and 12 months after diagnosis. Survey data on 1,054 control participants were also obtained for matching variables. Participants were asked whether or not they had each of 21 symptoms, and whether or not they attributed any activity limitation to each symptom. Results: Of 21 symptoms examined, prevalence of symptoms listed in Table 1 was significantly higher in cancer patients than in controls (p<0.05) at baseline. Though the prevalence of each symptom decreased significantly at follow up, each symptom remained significantly more prevalent than in the control group, with the exception of depression. Activity limitation attributed to 4 of the 5 symptoms listed in Table 1 was significantly higher than that of controls, and this difference persisted at follow up. Symptoms tended to cluster together amongst breast cancer patients. For example, at baseline, 73% of patients with depression also reported fatigue, and 30% of patients with pains in chest area also reported both fatigue and depression. These associations persisted at follow up. Symptoms were significantly correlated with each other at baseline (p<0.00005), with correlation coefficients ranging from 0.13 to 0.26, with most correlations remaining significant at follow up. Conclusion: In a large survey of breast cancer patients, symptoms were found to be associated with significant activity limitation, and tended to cluster together. This correlation persists at 12 months after diagnosis, even after treatment is complete. [Table: see text] No significant financial relationships to disclose.

Clinical Study of the Serotonin, Melatonin, Estradiol, and Adiponectin Hormones in Women with Breast Cancer in Thi – Qar Governorate -Iraq

2019 ◽  
Vol 10 (01) ◽  
Author(s):  
Hadeel Rashid Faraj1 ◽  
Husam Mohammed Kredy
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Healthy Subjects ◽  
Control Group ◽  
Serum Estradiol ◽  
Breast Cancer Patients ◽  
Healthy Individuals ◽  
Common Cause ◽  
Serum Serotonin ◽  
Apparently Healthy

Objective: Breast cancer is the most widely cancer among women, involving 18% of all female cancers, and worldwide, breast cancer is the fifth most common cause of cancer mortality. The study was designed to determine and compare the levels of Serotonin (ST), Melatonin (MT), Estradiol (E2), and Adiponectin (ADP) Hormones in Breast cancer patients and apparently healthy individuals. Material and Methods: Blood Serotonin (ST), Melatonin (MT), Estradiol(E2), and Adiponectin (ADP) Hormones levels were determined in 85 Breast cancer patients and 55 apparently healthy subjects. Results: The levels of serum Serotonin (ST), Melatonin (MT), and Adiponectin (ADP) Hormones were showing significant decrease in Breast cancer patients as compared to control group. ( P ≤ 0.05 ).While the level of serum Estradiol (E2) was showing significant increase in Breast cancer patients as compared to control group.( P ≤ 0.05 ). Conclusion: In Breast cancer patients, we finding decrease in Serotonin (ST), Melatonin (MT), and Adiponectin (ADP) Hormones. While we finding increase in Estradiol (E2) in Breast cancer patients as compared to control group.

Sign in / Sign up

Export Citation Format

Share Document